Oncotarget

Research Perspectives:

A beta version of life: p110β takes center stage

Hashem A. Dbouk and Jonathan M. Backer _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2010; 1:729-733. https://doi.org/10.18632/oncotarget.207

Metrics: PDF 2227 views  |   HTML 2968 views  |   ?  


Abstract

Received: December 24, 2010, Accepted: December 30, 2010, Published: December 30, 2010

The PI3K pathway is frequently activated in tumors, most commonly through p110α mutation or PTEN deletion. In contrast to p110α, p110β is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110α. In this perspective, we summarize recent data concerning the regulation of p110β, which shows that wild-type p110β acts like an oncogenic mutant of p110α. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110β regulation on GPCR-driven tumorigenesis.

 


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 207